Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia
✍ Scribed by M. Palma; L. Adamson; L. Hansson; P. Kokhaei; R. Rezvany; H. Mellstedt; A. Österborg; A. Choudhury
- Publisher
- Springer-Verlag
- Year
- 2008
- Tongue
- English
- Weight
- 259 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0340-7004
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Using a sensitive immunohistochemical technique and a specific monoclonal antibody (RFD-3), follicular dendritic cells (FDC) have been demonstrated in a significant proportion (6/12) of bone marrow samples from patients with nodular marrow involvement of B-cell chronic lymphocytic leukemia (B-CLL).
B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the slow and progressive accumulation of monoclonal apparently mature, CD5 ؉ B lymphocytes. The majority of circulating cells appear to be nondividing, and it has been suggested that a prolonged life span is mainly responsible for the a
Use of a nonlinear prediction method, such as machine learning, is a valuable choice in predicting progression rate of disease when applied to the highly variable and correlated biological data such as those in patients with chronic lymphocytic leukemia (CLL). In this work, decision-tree approach to
Differential scanning calorimetry (DSC) and complementary techniques were utilized to evaluate the sensitivity of B-cell chronic lymphocytic leukemia (B-CLL) cell samples in vitro exposed to cladribine or fludarabine in combination with mafosfamide. Mafosfamide, the active in vitro form of cyclophos